Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial
24/06/2025 12:33
June 24 (Reuters) - Nektar Therapeutics NKTR.O said on Tuesday its experimental eczema drug had met the main goals of a mid-stage study. Shares of the company were halted in premarket trading. (Reporting by Puyaan Singh in Bengaluru; Editing by Shreya Biswas) ((Puyaan.Singh@thomsonreuters.com;))
Recent news on Nektar Therapeutics
See all newsBrief: Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment
U.S. STOCKS ON THE MOVEx-Microsoft, 3M, Twilio
U.S. STOCKS ON THE MOVEx-Microsoft, Nike, Nektar Therapeutics
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says